• 1
    Rocca B, FithGerald GA. Cyclooxygenases and prostaglandins: shaping up the immune response. Int Immunopharmacol 2002; 2: 603.
  • 2
    FitzGerald GA, Loll P. COX in a crystal ball: current status and future promise of prostaglandin research. J Clin Invest 2001; 107: 1335.
  • 3
    Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001; 107: 1491.
  • 4
    Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001; 281: 1.
  • 5
    Krämer BK, Kammerl MC, Kömhoff M. Renal cyclooxygenase-2 (Cox-2). Physiological, pathophysiological, and clinical implications. Kidney Blood Press Res 2004; 27: 43.
  • 6
    Khan KN, Venturini CM, Bunch RT, et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 1998; 26: 612.
  • 7
    Nantel F, Meadows E, Denis D, Connolly B, Metters KM, Giaid A. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett 1999; 457: 475.
  • 8
    Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504.
  • 9
    Therland KL, Stubbe J, Thiesson HC, et al. Cyclooxygenase-2 is expressed in vasculature of normal and ischemic adult human kidney and is colocalized with vascular prostaglandin E2EP4 receptors. J Am Soc Nephrol 2004; 15: 1189.
  • 10
    Kömhoff M, Froone HJ, Klein T, Seyberth HW, Nüsing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997; 272: 460.
  • 11
    Koki A, Khan NK, Woerner BM, et al. Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol 2002; 507: 177.
  • 12
    Khan KN, Stanfield KM, Harris RK, Baron DA. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren Fail 2001; 23: 321.
  • 13
    Kömhoff M, Jeck ND, Seyberth HW, Gröne HJ, Nusing RM, Breyer MD. Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int 2000; 58: 2420.
  • 14
    Kammerl MC, Nüsing RM, Schweda F, et al. Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2. Clin Pharmacol Ther 2001; 70: 468.
  • 15
    Reinalter SC, Jeck N, Brochhausen C, et al. Role of cyclooxygenase-2 in hyper-prostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 2002; 62: 253.
  • 16
    Adegboyega PA, Ololade O. Immunohistochemical expression of cyclooxygenase-2 in normal kidneys. Appl Immunohistochem Mol Morphol 2004; 12: 71.
  • 17
    Khan KN, Stanfield KM, Harris RK, Baron DA. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Renal Fail 2001; 23: 321.
  • 18
    Tomasoni S, Noris M, Zappella S, et al. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 1998; 9: 1202.
  • 19
    Pfister AK, Crisalli RJ, Carter WH. Cyclooxygenase-2 inhibition and renal function. Ann Intern Med 2001; 134: 1077.
  • 20
    Reinhold SW, Fischereder M, Riegger GA, Krämer BK. Acute renal failure after administration of a single dose of a highly selective COX-2 inhibitor. Clin Nephrol 2003; 60: 295.
  • 21
    Matsuyama M, Yoshimura R, Hase T, Kawahito Y, Sano H, Nakatani T. Study of cyclooxygenase-2 in renal ischemia-reperfusion injury. Transplant Proc 2005; 37: 370.
  • 22
    Hausknecht B, Völkl S, Riess R, Gauer S, Goppelt-Struebe M. Expression of cyclooxygenase-2 in biopsies obtained from human transplanted kidneys undergoing rejection. Transplantation 2003; 76: 109.
  • 23
    Rangel EB, Moura LA, Franco M, Pacheco-Silva A. Up-regulation of cyclooxygenases during renal allograft rejection. Clin Transplant 2005; 19: 543.
  • 24
    Paivaniemi OE, Maasilta PK, Alho HS, Wolff CH, Salminen US. Cyclooxygenase-2 expression in experimental post-transplant obliterative bronchiolitis. J Pathol 2004; 204: 340.
  • 25
    Yang X, Ma N, Szabolcs MJ, et al. Upregulation of COX-2 during cardiac allograft rejection. Circulation 2000; 101: 430.
  • 26
    Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and tranplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 646.
  • 27
    Höcherl K, Kees F, Krämer BK, Kurtz A. Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression. Kidney Int 2004; 65: 2071.
  • 28
    Masferrer JL, Seibert K, Zweifel B, et al. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992; 89: 3917.
  • 29
    Martin M, Neumann D, Hoff T, et al. Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int 1994; 45: 150.
  • 30
    Höcherl K, Dreher F, Vitzthum H, et al. Cyclosporine A suppresses cyclooxygenase-2 expression in the rat kidney. J Am Soc Nephrol 2002; 13: 2427.
  • 31
    Migita K, Tanaka H, Okamoto K, et al. FK506 augments glucocorticoid-mediated cyclooxygenase-2 down-regulation in human rheumatoid synovial fibroblasts. Lab Invest 2000; 80: 135.
  • 32
    Chang CT, Hung CC, Yang CW, Vandewalle A, Wu MS. Cyclosporine decreases prostaglandin E2 production in mouse medullary thick ascending limb cultured cells. Transpl Int 2005; 18: 871.
  • 33
    Feitoza CQ, Camara NO, Pinheiro HS, et al. Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury. Int Immunopharmacol 2004; 5: 79.
  • 34
    Ma N, Szabolcs MJ, Sun J, et al. The effect of selective inhibition of cyclooxygenase (COX)-2 on acute cardiac allograft rejection. Transplantation 2002; 74: 1528.
  • 35
    Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
  • 36
    Gibbons CP, Wiley KN, Lindsey NJ, et al. Cortical and vascular prostaglandin synthesis during renal allograft rejection in the rat. Transplantation 1987; 43: 472.
  • 37
    Tönshoff B, Busch C, Schweer H, Schärer K, Seyberth HW. In vivo prostanoid formation during acute renal allograft rejection. Nephrol Dial Transplant 1993; 8: 631.
  • 38
    Li Q, Lopez JS, Caspi RR, et al. Suppression of S-antigen-induced experimental autoimmune uveoretinitis in Lewis rats by oral administration with CGS-13080, a thromboxane synthetase inhibitor. Exp Res 1993; 57: 601.
  • 39
    Ruiz P, Rey L, Spurney R, Coffman T, Ciciana A. Thromboxane augmentation of alloreactive T cell function. Transplantation 1992; 54: 385.
  • 40
    Kömhoff M, Wang JL, Cheng HF, et al. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 2000; 57: 414.
  • 41
    Plescia OJ, Smith AH, Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci USA 1975; 72: 1848.
  • 42
    Barrios-Rodiles M, Chadee K. Novel regulation of cycloocygenase-2 expression and prostaglandin E2 production by IFN-γ in human macrophages. J Immunol 1998; 161: 2441.
  • 43
    Iniguez MA, Punzon C, Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 1999; 163: 111.
  • 44
    Vio CP, An SJ, Cespedes C, et al. Induction of cyclooxygenase-2 in thick ascending limb cells by adrenalectomy. J Am Soc Nephrol 2001; 12: 649.
  • 45
    Goppelt-Struebe M, Esslinger B, Kunzendorf U. Failure of cyclosporin A to induce transforming growth factor beta (TGF-β) synthesis in activated peripheral blood lymphocytes. Clin Transplant 2003; 17: 20.
  • 46
    Gossmann J, Radounikli A, Bernemann A, et al. Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? Kidney Blood Press Res 2001; 24: 111.
  • 47
    Perez R, Stevenson F, Johnson J, et al. Sodium butyrate upregulates Kupffer cell PGE2 production and modulates immune function. J Surg Res 1998; 78: 1.
  • 48
    Blaheta RA, Nelson K, Oppermann E, et al. Mycophenolate mofetil decreases endothelial prostaglandin E2 in response to allogeneic T cells or cytokines. Transplantation 2000; 69: 1977.
  • 49
    Hilkens C, Snijders A, Vermeulen H, van der Meide P, Wierenga E, Kapsenberg M. Accessory cell-derived interleukin-12 and prostaglandin E2 determine the level of interferon-gamma produced by activated human CD4+ T cells. Ann N Y Acad Sci 1996; 795: 349.
  • 50
    van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995; 181: 775.
  • 51
    Takayama K, Garcia-Cardena G, Sukhova GK, et al. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002; 277: 441.
  • 52
    Gilroy DW, Colville-Nash PR, Willis D, et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5: 698.